key: cord-0692250-lvjtcm08 authors: Oscanoa, Teodoro J.; Romero-Ortuno, Roman; Carvajal, Alfonso; Savarino, Andrea title: A pharmacological perspective of Chloroquine in SARS-CoV-2 infection date: 2020-07-04 journal: Int J Antimicrob Agents DOI: 10.1016/j.ijantimicag.2020.106078 sha: 103f4d390e8b8a2ab6b34d6e79a76bde61d39070 doc_id: 692250 cord_uid: lvjtcm08 The pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is having serious consequences on health and the economy worldwide. All evidence-based treatment strategies need to be considered to combat this new virus. Drugs need to be considered on scientific grounds of efficacy, safety and cost. Chloroquine (CQ) and hydroxychloroquine (HCQ) are old drugs used in the treatment of malaria; in addition, their antiviral properties have been previously studied, including in coronaviruses, where evidence of efficacy has been found. The safety of CQ and HCQ has been studied for over 50 years. In the current race against time triggered by the SARS-CoV-2 pandemic, the search for new antivirals is very important. However, consideration should be given to old drugs with known anti-coronavirus activity, such as CQ and HCQ; these could be integrated into current treatment strategies while novel treatments are awaited, also in light of the fact that they display an anticoagulant effect that facilitates the activity of low MW heparin, aimed at preventing ARDS-associated thrombotic events. The safety of CQ and HCQ has been studied for over 50 years, however, recently published data raise concerns for cardiac toxicity of CQ/HCQ in patients with COVID-19. The review that we here provide also reexamines the real information provided by some of the published alarming reports although concluding that cardiac toxicity should in any case be stringently monitored with patients with CQ/HCQ. Betacoronavirus originating from bats. SARS-CoV-2 has approximately 79% sequence similarity with SARS-CoV and 50% with MERS-CoV [2] . SARS-CoV-2 is postulated to use the Angiotensin Converting Enzyme 2 (ACE2) receptor to infect the human cell, based on its similarity to SARS-CoV in its receptor binding domain structure [2, 16] . Wang et al. have reported that the infection mechanism based on the use of the human ACE2 cell receptor is common in SARS-CoV, MERS-CoV and SARS-CoV-2; however, there may be a difference with SARS CoV-2, in that the latter has the ability to increase the expression of ACE2 in the host cell, which facilitates its infection and spread [17] . The structure of the SARS-CoV-2 virion is comprised by a spike glycoprotein (S), a hemagglutinin-esterase dimer (HE), a membrane glycoprotein (M), an envelope protein (E), the nucleocapsid protein (N) and the RNA genome [2] . The S glycoprotein is highly glycosylated and uses an N-terminal signal sequence to enter the endoplasmic reticulum (ER) and bind to receptors of the human host cell. The S glycoprotein determines the tissue tropism of the virus, that is, the SARS-CoV-2 affinity towards the host cell. SARS-CoV-2 binds to the ACE2 receptor expressed in pneumocytes [17, 18] . The binding to the ACE2 receptor triggers conformational changes in the S glycoprotein, allowing its cleavage by the transmembrane protease TMPRSS2 of S glycoprotein and the release of S fragments in the cell supernatant, which inhibit virus neutralization by antibodies [19] . Coronaviruses are so named because the S glycoprotein that surrounds the virus forms large bumps giving the impression of a crown (from the Latin "corona", in turn derived from the Greek "Korone") [20, 21] . In most coronaviruses, S is cleaved by a furin-like protease from the host cell into two separate polypeptides, S1 and S2. The nucleocapsid (N) protein binds to RNA in vitro, is highly phosphorylated and has the function of binding the viral genome to the replicase-transcriptase complex (RTC) and subsequently packaging the genome encapsulated in viral particles. The envelope glycoprotein (E) is probably a transmembrane protein, with functions of acting as an ion channel, facilitating the assembly and release of the virus. Membrane protein (M) is present as a dimer in the virion and can have two different conformations to allow promote membrane curvature and joining the nucleocapsid. Finally, the hemagglutinin esterase (HE) dimeric glycoprotein binds to sialic acids in surface glycoproteins [16] . Studies have shown that CQ/HCQ may have antiviral action through the following mechanisms (Fig 1) : Prevention of virus entry into the cell. Many viruses invade the cell using the endocytic pathway [22, 23] . CQ alters the pH of endosomes and therefore may have an inhibitory effect on viral infections such as those causing Borna disease [24] , avian leukosis [25] , Zika [26] , influenza [27] , Japanese encephalitis [28] and dengue [29, 30] . Altered virus replication. Viruses use the host cell machinery to produce their progeny. Some enveloped viruses additionally require posttranslational modifications of the envelope glycoproteins for the formation of new viruses; this occurs within the endoplasm and vesicles of the trans-Golgi network (TGN). This complex process requires enzymes such as proteases and glycosyltransferases, which in some cases require a medium with a low pH. By raising the pH of endosomes, CQ / HCQ may cause dysfunction of several enzymes among which are glycosyltransferases. This mechanism may explain possible effects of CQ / HCQ inhibiting budding of Mayaro virus particles [31] , inducing the accumulation of non-infectious herpes simplex virus 1 particles in the TGN [32] and inhibiting the replication of viruses of the family Flaviviridae by affecting the proteolytic process of conversion of prM to M protein of flavivirus [33] . In-vitro and in-vivo studies have suggested that CQ alters the glycosylation pattern of the HIV-1 gp120 envelope and inhibits replication of HIV in CD4+ T cells, producing non-infectious retrovirus particles [34] [35] [36] [37] . Animal studies have suggested that CQ can inhibit autophagy in the lungs of mice with H5N1 avian influenza and reduce alveolar epithelial damage [38] . In mice studies, CQ can prevent vertical transmission of the Zika virus by maternal-fetal pathway [39] . such as TNF-α, IP-10, IL-6, and IL-8 [58, 59] . A similar phenomenon called "cytokine storm" has been observed in patients with SARS-CoV-2, because they display high levels of IL-1B, IFN-γ, IP-10 and MCP1, which probably lead to activated T-helper-1 cell responses. Patients with severe SARS-CoV-2 infection requiring admission to the Intensive Care Unit (ICU) had higher concentrations of G-CSF, IP--α than those who did not require admission to the ICU, suggesting that the "cytokine storm" was associated with the severity of the disease [60] . In line with the self-limiting nature of the disease in a significant proportion of patients, SARS-CoV-2 infection may also initiate increased secretion of T-helper-2 cytokines (e.g. IL-4 and IL-10) that suppress inflammation, a phenomenon which differs from SARS-CoV infection. In the pathophysiology of this "cytokine storm" associated with SARS-CoV-2, the ACE2 receptor seems to play an important role. The hypothesis that ACE2 is a gene sensitive to virus infection especially by SARS-CoV-2 has been proposed; the inducibility of ACE2 by inflammatory cytokines also implies that the "cytokine storm" caused by 2019-nCoV not only damages the host tissues but can also accelerate the spread of the virus [60, 61] . Therefore, induction by CQ/HCQ of ACE2 subglycosylation could hypothetically have immunomodulating effects related or not to the aforementioned inhibition by CQ of cytokine production, chemokines and other mediators of inflammation. CQ and HCQ have similar pharmacokinetics, with rapid gastrointestinal absorption and renal elimination. From many years of experience in malaria, two main differences between the two drugs are known: CQ is toxic at high doses (therefore it is typically used at higher doses for a short time or low doses over a long period), whilst HCQ can be used in high doses for long periods with very good tolerance [53] . After oral administration, CQ / HCQ are widely and slowly distributed throughout the body, and this is due to extensive sequestration in tissues, particularly in liver, spleen, kidney, lung, melanin-containing tissues and, to a lesser extent, brain and spinal cord [62] . This large apparent volume of distribution confers to CQ/HCQ a relatively short plasma half life. CQ/HCQ accumulates in many cell types. Cell permeation by CQ/HCQ can be deduced by studies conducted in human erythrocytes and Plasmodium falciparum cells [63] [64] [65] . CQ and HCQ are weak bases, the main cell permeant is the unprotonated form of CQ which represents a minority of the extracellular CQ pool. Due to the Henderson-Hasselbach equation, however, part of the remaining CQ portion dissociates to maintain equilibrium at the physiological pH, thus allowing the drug to gradually enter the cells. As passage through the plasma membrane is due to diffusion and not to active transportation, the process does not become saturated, and the initial intracellular accumulation of the drug is dose-dependent. This pharmacokinetic property allows administering loading doses in order to reach the desired intracellular concentrations more quickly. Once inside the cells, CQ/HCQ is protonated at a rate inversely proportional to the pH, again, according to the Henderson-Hasselbach law [36] . Within the intracellular compartment, the drug is actively transported to the acidic intracellular organelles where a large amount of the drug becomes entrapped due to protonation associated with the low pH. CQ and HCQ enter the endosome, Golgi vesicles and lysosomes, where the pH is low, and in this medium most of the CQ and HCQ molecules are positively charged [66] . In whole blood the drug is approx. 4-5 fold more concentrated than in plasma due to this intracellular accumulation [67] . For this reason, whole blood levels of the drug represent a more meaningful marker for its pharmacokinetics than the plasma levels. Among the different cell types, the drug is largely accumulated in tissue macrophages which are ubiquitous. These properties represent the basis of the apparently large volume of distribution of the drug. Of interest for COVID-19 therapy, CQ/HCQ has been calculated to accumulate in the lungs. The endosomal therasurization of the aminoquinolines also represents a basis for their slow excretion. CQ/HCQ is maintained within the body for prolonged periods after its suspension. For example, HCQ has a half-life of 2963 hours [68] . Clearance to the extracellular environment of CQ and HCQ is by exocytosis and / or through the action of the multi-drug resistance protein MRP-1, a cell surface drug transporter belonging to the ATP-binding cassette family, which also includes P-glycoprotein [37, 69] . HCQ is metabolized in the liver into three active metabolites, desethylchloroquine, desethylhydroxychloroquine, and bisdesethylhydroxychloroquine [70] . Desethylchloroquine possess anti-Zika virus activity [71] . All the N-dealkylated metabolites have been implicated in heart failure and retinopathy, due to long-term treatment with chloroquine [72] . Chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days [73] . CQ clearance is by the renal route, 38% of the administered dose is eliminated without changes [74] . In vitro studies CQ has been shown to inhibit the replication of SARS-CoV-1 in HRT-18 cells, in addition to preventing death induced by human coronavirus OC43 in newborn mice; that is, protection is achieved by the transplacental route or by means of breast milk [75] . The anti-coronaviral activity of CQ has been reported in the human fetal lung cell line, L132, infected with HCoV-229E; in this scenario, CQ significantly decreased viral replication at lower concentrations well within the range reported in blood during in clinical use [76] . In a study with BHK-21 cells infected with recombinant virus rHCoVs-OC43 labeled with Renilla luciferase, CQ inhibited the replication of HCoV-OC43 in vitro [77] . There are three in vitro studies of the activity of CQ or HCQ against SARS-CoV-2 using Vero E6 cells Liu et al. studied the in vitro anti-SARS-CoV-2 activity of HCQ using VeroE6 cells from green monkey kidney (ATCC-1586), finding that it efficiently inhibits SARS-CoV-2 infection [4] .Additionally, the study confirmed that HCQ inhibits the entry of SARS-CoV-2 into cells, as well as the stages after SARS-CoV-2 entry; and CQ had similar effects [4] . The results of a number of clinical trials [80] [81] [82] [83] [84] and observational studies [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] have been reported so far, many of which presenting methodological limitations, due to duress conditions during a the conditions due to an unexpected pandemics (Table 1) . Two studies also suffer from poor reporting, with no dosage being declared [87, 93] and one of them including in the HCQ arm patients with worse baseline characteristics than the control group [93] . Among the trials reporting the dosages adopted, the results are reminiscent of those reported in the context of HIV/AIDS, another disease in which CQ/HCQ use was postulated to be beneficial because of both reported antiviral activity and inhibition of immune activation [100] , showing dose dependency of the positive outcomes. Seven of the COVID-19 clinical studies were conducted with a median dosage of 400 mg/day of HCQ, with or without a loading dose and an association with azythromycin. Two of these [including one randomized clinical trial (RCT)] resulted in positive outcomes and five (again, including one RCT) report negative results. One of these studies, though, reported results comparing the use of HCQ with that of another antiviral agent [91] . Among the studies using 600 mg of HCQ daily, four reported positive outcomes and three did not. Five of these studies were only observational (three with positive and two with negative results) [86, 90, 96, 97, 101] . Some of the studies using daily 600mg HCQ studies associated HCQ with azythromycin apart from an observational study which showed negative results. [82, 94, 102] . One RCT of HCQ using an LD of 1200 mg on the first day followed by 800 mg of the drug daily had a negative outcome [80] .This dosage of HCQ is slightly lower than the maximum dosage administered to patients with autoimmune diseases. This trial, however, was biased by the background antiviral therapy. In the first version of the clinical trial that the authors filed [80] the authors showed that, after stratification of the patients by background antiviral therapy, the use of HCQ decreased the risk for hospitalization. The reason why the authors removed this analysis in the subsequent version of the study is unclear [80] . As of May 17 2020, the study has not yet been peer-reviewed. Both articles reporting results on CQ (1000 mg daily), state that there was a positive outcome in terms of virus negativization [85, 95] . Finally, one study [103] reports results of a trial including two arms, one of which treated with the maximum dosage of CQ so far administered to humans (1200 mg daily). The trial was interrupted because of significant toxicity resulting in increased number of deaths. Another recent study merits to be dealt with in particular detail because of the level of alarm raised through its large media coverage and the elevated number of people on whom it was conducted [101] . After conducting a retrospective analysis on 671 hospitals in six continents, Mehra et al. conclude that CQ and HCQ, particularly in combination with macrolide antibiotics, increase the number of deaths in hospitalized patients with COVID-19 and that this excess mortality is associated with increased arrhythmias. The study, however, is biased by non-homogeneous distribution of pre-existing risk factors. For example, the treatment groups had higher incidence of current cigarette smoking, hypertension, and a larger body mass index (BMI), all factors in general associated with poorer prognoses. Some of these factors such as hypertension or BMI resulted to be independent predictors of mortality according to the analyses done by the same authors. Although none of these factors was significantly higher in the CQ/HCQ groups, it cannot be excluded that their cumulative association in these groups may have been the fatal determinant for increased mortality. Moreover, it is not clear why only patients treated with remdesivir but not those treated with any of the other antivirals were excluded from the analysis. There were background antiviral interventions, and the distribution of the different antivirals in the CQ/HCQ, non-CQ/HCQ groups is not reported. It is known that some antivirals such as lopinavir/r, when administered at full dosages can increase the incidence of arrhythmias [104] and this analysis should therefore have been reported. Finally, the study filed to detect the contribution of cigarette smoking to the incidence of arrhythmias, an association which is largely documented in literature [105] . Despite these limitations, the study supports the notion of cautious monitoring of patients receiving chloroquine/hydroxychloroquine, in particular those who have independent risk factors potentially associated with higher mortality from COVID-19. The toxicity profile thus showed a pattern similar to that observed with the positive outcomes, with higher numbers of events observed with the highest dosages of CQ/HCQ. The study of Borba et al. [103] administering the highest CQ dosage, however, is biased by the fact that the authors administered such a high dosage of CQ concomitantly with azithromycin, for reasons that will be apparent below. In general, the results so far obtained can be explained by recent calculations taking into account the pharmacokinetics of CQ/HCQ. Taking into account the mathematical model developed by Goncalves et al. [106] recent pharmacokinetic analyses [107] and some immune modulating properties of the drug [108] . Tarek and Savarino calculated that CQ/HCQ may have a limited impact on viral clearance, being evident only within a narrow window of tissue concentrations immediately below those causing toxicity [109] . The results of this modeling study also highlight a problem underlying many of the aforementioned clinical studies, which were conducted in patients already hospitalized: an antiviral effect of HCQ is to be expected when the drug is administered immediately early after diagnosis, before patients are hospitalized. Finally, in regard of very early administration, a recently published study shows a potential for HCQ as a post-exposure prophylaxis [110] . The study reports on a post-exposure prophylaxis regimen that was conducted in 211 patients and health workers following exposure to two infected healthcare workers. After a median period of 10 days of preventive treatment with hydroxychloroquine (400 mg / day), nobody tested positive for the virus. Unfortunately there was no control group. The results of a controller clinical trial of HCQ prophylaxis will soon be available [111] . Adverse drug reactions (ADRs) related to CQ/HCQ can be generally divided into two types, depending on the duration of the administration. The first type of ADR occurs when administered for a short time (<1 month), as in the treatment or prophylaxis of malaria ("acute toxicity"). The second type of ADR appears when it is administered for long periods of time (years), as occurs in the treatment of systemic lupus erythematosus and rheumatoid arthritis, and produced by accumulation of the drug in the body ("cumulative toxicity") [112] . Both types of CQ/HCQ-induced ADRs have been extensively studied, for more than 50 years, as literally hundreds of tons of the drug have been administered to more than 200 million malaria patients [113] . Severe but very rare ADRs have been observed when administered for several years and occur due to the accumulation of the drug in the body. Regarding the safety of CQ / HCQ and its administration schedules for SARS-CoV-2, it is possible to make a comparison with acute compare it with that reported during administration in the treatment of malaria. For SARS-CoV-2 treatment, a duration of 5 to 20 days has been recommended according to the severity of the case, with a maximum dose of 1000 mg / day of CQ, or the equivalent of HCQ. In the treatment of malaria, the dose is 25mg / kg for 3 days (in a 60 kg patient, 1500mg / day) [114] . The most frequent CQ / HCQ ADRs when administered for malaria are pruritus (6-50.9%), dizziness (9.6-22.69%), vomiting (1-15.8%), abdominal pain (2-13.3%), headache (9.6-13.2%), insomnia (9.6%), nausea (6.53-11.3%), and asthenia (5.3-9.6%) [115] [116] [117] [118] . The most serious but very rare ADRs have been reported in treatment for more than 5 years, among the two most important being cardiotoxicity and retinopathy. Cardiotoxicity during treatment for malaria is very rare; clinically relevant prolongation of the QTc interval has been observed; and no cases of retinopathy have been reported when administered for this indication [119] . Reported cases of severe arrhythmias (torsades de pointes) or sudden death have been reported in patients on more than 5 years of treatment due to autoimmune diseases [120] . Safety concerns have been raised for cardiac toxicity also during acute treatment with HCQ [121] . In this regard, important insight on safety issues can be derived from a recent survey on data from almost one million patients with autoimmune disease treated with HCQ [122] . The results show that there is no risk for significant prolongation of the QT interval in patients treated with HCQ alone for less than 30 days in comparison with those treated with sulfasalazine. On the other hand, the risk was increased when HCQ was used in combination with azithromycin. It may be argued that, because COVID-19 causes cardiac problems, the cardiac toxicity of HCQ can be enhanced also in the short term. These considerations can be rejected in light of the fact that also autoimmune diseases such as lupus and rheumatoid arthritis for which HCQ has been used for decades, can affect the heart. Moreover, a number of guidelines have been issued to prevent an circumvent HCQ-related cardiac toxicity in patients with COIVD-19 [121, 123, 124] ; would be highly recommended at this stage. It has been hypothesized that also a short HCQ treatment might be detrimental in the treatment of COVID-19, because the drug may impair innate immunity and thus deprive the organism from an important weapon of self-defense against the virus [125] . These considerations however are only theoretical and seem not to be applicable in the context of treatment of an acute infectious disease such as COVID-19. First, an investigation conducted on a large number of patients treated with HCQ for lupus erythematosus showed that in fact the drug decreases the infectious events [126] . Second, the HCQ analogue CQ was shown to significantly increase cell-mediated responses in response to a viral antigen [108, 127] . Cell-mediated responses have recently been shown to play a major part in protection against SARS-CoV-2 in vivo [128] Chronic treatment safety issues In a systematic study on chronic use (3.25 to 7.9 years) of CQ/HCQ in patients with systemic lupus erythematosus, HCQ had fewer adverse reactions than CQ. The proportions of ADRs were nausea (7-12%), diarrhea (18%), myopathy (1.3%), headache (1.3% -12%), ototoxicity (0.6%), and dermatological such as urticaria (0.6 % -12%) [119] . The frequency of cardiotoxicity such as conduction disorders (0-4%) and cardiomyopathy (0-1.3%) were very rare [129] . The frequency of retinal toxicity ranged from 0.33% to 16%, and a study compared the frequency between CQ and HCQ (19% vs. 0%) [130] . CQ / HCQ-induced cardiotoxicity is related to certain risk factors such as advanced age, female sex, prolonged duration of therapy (> 10 years), high daily dose per kilogram, pre-existing heart disease and kidney failure [131] . Chatre et al. conducted a systematic study on cardiotoxicity associated with CQ / HCQ; of the total cases, 15% were patients on short-term treatment (malaria), and the remaining were patients on prolonged treatments for connective tissue diseases [112] ; they found that cardiotoxicity was predominant in women (65%); the mean use of CQ / HCQ was 7 years (range 3 days to 35 years), higher in CQ users than HCQ, and the mean cumulative dose was 1235 g for HCQ and 803 g for CQ. [112] .Acute cardiotoxicity occurs due to alteration in ion channels with a destabilizing effect on the membrane, increased QT interval, a negative inotropic effect and atrioventricular block. On the other hand, cumulative cardiotoxicity occurs by accumulation of the drug in the body, which increases lysosomal pH, with alteration of lysosomal protein degradation, accumulation of autophagosomes, phospholipids, and glycogen with vacuolization of myocytes [112] . Keratoplasty and retinopathy induced by CQ / HCQ has not been described when used as antimalarial. The frequency is very low, and they have been described in patients who used HCQ for more than 10 years and at high dose [132] . The Incidence of HQC retinopathy is 0.4% in patients whose daily dosage is >6.5 mg/kg or who have taken HCQ continuously for > 10 years [133] [134] [135] . Bilateral pigmentary retinopathy induced by CQ / HCQ begins with subtle paracentral scotomas, followed later by "bull's-eye" maculopathy, which is characterized by a ring of retinal pigment epithelium (RPE) in the macular area closest to the fovea and the final stage with generalized RPE and atrophic retina with loss of central, peripheral and night vision. Risk factors for CQ retinopathy are doses greater than 2.3 mg / kg and HCQ > 5.0 mg / kg, duration of therapy greater than 5 years, kidney failure, drug interaction (e.g. Tamoxifen), and previous macular disorders that make it difficult note the changes in the follow-up eye exams [120, 136] . Currently Due to toxicity issues emerging, they then recommended that CQ/HCQ be not prescribed outside the hospital setting or the context of registered clinical trials [149] The Italian Drug Agency (AIFA), having first authorized CQ/HCQ treatment also for non-hospitalized COVID-19 patients [150] , has stopped recommending the use of CQ/HCQ for treatment of COVID-19 [151] , following the aforementioned report of Mehra et al. [101] . Following the same report [101] , also France has stopped recommending the use of CQ/HCQ [152] . The Spanish drug regulatory agency has instead decided to maintain the recommendation for HCQ treatment, due to the limitations of the aforementioned report [153] . In the current context of the SARS-CoV-2 pandemic, with disastrous health and economic consequences, it is important to consider all the strategies to combat it, in relation to drug selection, which will always be based on their efficacy and safety. There has been significant research on the possible antiviral action of CQ / HCQ. Available online: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks- -the-media-briefing-on-covid Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Systematic Review of the Registered Clinical Trials of Coronavirus Disease A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 The use of antimalarial drugs against viral infection Malaria research in the post-genomic era Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate Severe acute respiratory syndrome Structural basis for the recognition of SARS-CoV-2 by fulllength human ACE2. Science (80-) 2020 Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov doi: bioRxiv preprint n Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development Multiscale perspectives of virus entry via endocytosis From endocytosis to membrane fusion: emerging roles of dynamin in virus entry Mechanism of Borna disease virus entry into cells Endocytosis Is a Critical Step in Entry of Subgroup B Avian Leukosis Viruses an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models In vitro inhibition of human influenza A virus replication by chloroquine Japanese Encephalitis Virus Enters Rat Neuroblastoma Cells via a pH-Dependent, Dynamin and Caveola-Mediated Endocytosis Pathway Chloroquine Inhibits Dengue Virus Type 2 Replication in Vero Cells but Not in C6/36 Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells Characterization of Herpes Simplex Virus-Containing Organelles by Subcellular Fractionation: Role for Organelle Acidification in Assembly of Infectious Particles Acidotropic amines inhibit proteolytic processing of flavivirus prM protein Inhibition of Human Immunodeficiency Virus Infectivity by Chloroquine Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes Effects of chloroquine on viral infections: an old drug against today's diseases New insights into the antiviral effects of chloroquine Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells Antimalarial Drugs Inhibit Phospholipase A2 Activation and Induction of Interleukin lβ and Tumor Necrosis Factor α in Macrophages: Implications for Their Mode of Action in Rheumatoid Arthritis The anticoagulant properties of chloroquine dihydrochloride (Aralen), hydroxychloroquine sulfate (Plaquenil), and quinine dihydrochlorine. Results of tests in vitro In vitro inhibition of the activation of the human complement and coagulation systems by chloroquine Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism Interactions between coagulation and complement-their role in inflammation Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE) Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Kinetic Mechanism of Quinone Oxidoreductase 2 and Its Inhibition by the Antimalarial Quinolines † Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza Immunopathogenesis of coronavirus infections: implications for SARS Elucidating the molecular physiopathology of acute respiratory distress syndrome in severe acute respiratory syndrome patients T cell-mediated immune response to respiratory coronaviruses Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei Pharmacokinetics of Quinine, Chloroquine and Amodiaquine Uptake of chloroquine by human erythrocytes Chloroquine Transport in Plasmodium falciparum . 1. Influx and Efflux Kinetics for Live Trophozoite Parasites Using a Novel Fluorescent Chloroquine Probe Chloroquine Accumulation by Purified Plasma Membranes from Plasmodium falciparum Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus Direct binding of chloroquine to the multidrug resistance protein (MRP) Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax Antimalarial drugs and their metabolites are potent Zika virus inhibitors Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease Clinical Pharmacokinetics and Metabolism of Chloroquine Steady state disposition of chloroquine in patients with rheumatoid disease Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb cl Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. MedRxiv Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19 Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a sixday follow up: A pilot observational study Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a sixday follow up: an observational study Running title: Hydroxychloroquine-Azithromycin and COVID-19 Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a rando Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers Smoking and incidence of atrial fibrillation: Results from the & Smith P. Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo Pharmacokinetic bases of the hydroxychloroquine response in COVID-19: implications for therapy and prevention Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature Cardiotoxicity of antimalarial drugs World Health Organization. WHO model prescribing information : drugs used in parasitic diseases Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria Treatment of adults with acute uncomplicated malaria with azithromycin and chloroquine in India, Colombia, and Suriname Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review What is new in Recommendations on Ophthalmological Screening in Patients Treated with Chloroquine and Hydroxychloroquine? Update and Literature Review Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) & Casajust P. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid widespread use for COVID-19: a multinational, network cohort and self-controlled case series study SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Hear Rhythm Cloroquina e Hidroxicloroquina en el tratamiento de pacientes con COVID-19 Rethinking the role of hydroxychloroquine in the treatment of COVID-19 Predictors of major infections in systemic lupus erythematosus Enhancement of T cellmediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus Hydroxychloroquine-related retinal toxicity Interim clinical guidance for patients suspected of/confirmed with covid-19 in Belgium-06 Handbook of COVID-19 Prevention and Treatment Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19). Version 3.0 National Institute for the Infectious Diseases "L. Spallanzani" IRCCS. Recommendations for COVID-19 Clinical Management Handbook for the care of people with disease-COVI 19.SIMIT Italian Society of Infectious and Tropical Diseases SECTION Regione Lombardia Edition 2.0 COVID-19 Management Guidelines -Pakistan Chest Society Medicine COVID-19 Resource Site. 20/5/2020 Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie à SARS CoV2 2020 Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 Guía terapéutica para COVID 19 del Ministerio de Salud Publica Ecuador An Algorithmic Approach to Diagnosis and Treatment of Coronavirus Disease 2019 (COVID-19) in Children: Iranian Expert's Consensus Statement FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems The Italian Drug Agency (AIFA) AIFA sospende l'autorizzazione all'utilizzo di idrossiclorochina per il trattamento del COVID-19 al di fuori degli studi clinici France Bars Use Of Hydroxychloroquine In COVID-19 Cases La Aemps ve grietas en el estudio de 'The Lancet' y niega haber recibido alertas por hidroxicloroquina The median time to achieve an undetectable viral RNA was shorter in CQ than in non-chloroquine(absolute difference in medians -6.0 days; 95% CI -6.0 to -4.0 P < 0.0001) -The duration of fever is shorter in CQ (geometric mean ratio 0.6; 95% CI 0.5 to 0.8; P =0.0029;). LPV/r appears to be more effective than HCQ at preventing progression to severe disease in patients with was significantly more common in the HCQ group than in the LPV/r group (41% [11/27] HCQ treatment was an independent predictor of lower mortality (p=0,003, 95% CI 0,012 -0,402). In a cohort of patients hospitalised with COVID-19, hydroxychloroquine treatment with 800mg added loading dose increased survival when patients were admitted in early stages of the disease.